Clinical trials · Boston, MA
Multiple myeloma clinical trials in Boston
We’re tracking 56 recruiting multiple myeloma studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06138275RecruitingPhase 2
Elranatamab for relapsed multiple myeloma after Abecma
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Boston, MassachusettsAges 18 years+ - NCT06152575RecruitingPhase 3
Study of elranatamab for multiple myeloma that returned after other treatments
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Boston, MassachusettsAges 18 years+ - NCT06153251RecruitingPhase 1
Study of BMS-986453 for Relapsed or Refractory Multiple Myeloma
This study tests a new drug, BMS-986453, for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if it is safe and works against the cancer.
Boston, MassachusettsAges 18 years+ - NCT05714839RecruitingPhase 1/Phase 2
Belantamab for multiple myeloma
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT07377435RecruitingPhase 1
Vaccine after CAR-T therapy for multiple myeloma
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Boston, MassachusettsAges 18 years+ - NCT03689595Enrolling by invitation
PROMISE study: Predicting myeloma risk in high-risk groups
This study uses a blood test to find early signs of myeloma in people at higher risk, such as those with a family history or African ancestry. It aims to predict who might develop myeloma before symptoms appear.
Boston, MassachusettsAges 30 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Boston, MassachusettsAges 18 years+ - NCT07266441RecruitingPhase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT05651932RecruitingPhase 1
Test of an MMSET inhibitor for relapsed multiple myeloma
This Phase 1 trial tests a new drug that targets MMSET in people whose multiple myeloma has returned or not responded to prior treatment. It aims to find a safe dose and see whether it can shrink myeloma in this setting.
Boston, MassachusettsAges 18 years+ - NCT06232044RecruitingPhase 1/Phase 2
Testing a new drug combo for returning multiple myeloma
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Boston, MassachusettsAges 18 years+ - NCT06356571RecruitingPhase 2
Isatuximab with carfilzomib and dexamethasone for multiple myeloma
This trial tests a new combination of drugs (isatuximab, carfilzomib, and dexamethasone) given as shots under the skin for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if this mix works better than previous options.
Boston, MassachusettsAges 18 years+ - NCT02343042RecruitingPhase 1/Phase 2
Selinexor with standard therapies for multiple myeloma
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
Boston, MassachusettsAges 18 years+ - NCT07393282RecruitingPhase 3
Comparing two treatments for high-risk smoldering multiple myeloma
This trial tests a new drug called linvoseltamab against an existing treatment, daratumumab, for people with a high-risk form of smoldering multiple myeloma. The goal is to see which one works better to delay or prevent the disease from becoming active multiple myeloma.
Boston, MassachusettsAges 18 years+ - NCT06518551RecruitingPhase 1/Phase 2
Elotuzumab, Iberdomide, and Dexamethasone after Ide-cel for multiple myeloma
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
Boston, MassachusettsAges 18 years+ - NCT05646576Recruiting
Palliative care support during blood cancer cell therapy
This trial studies whether adding palliative care (comfort-focused care to reduce stress and symptoms) helps people during adoptive cell therapy for blood cancers. It may help improve quality of life while you’re receiving the therapy.
Boston, MassachusettsAges 18 years+ - NCT05706766Recruiting
Exercise coaching before stem cell transplant for multiple myeloma
This trial studies whether a structured exercise program before an autologous (your own cells) stem cell transplant can improve health and fitness in people with multiple myeloma. The goal is to safely prepare your body for transplant, and the study includes fitness testing and ongoing exercise training.
Boston, MassachusettsAges 18 years+ - NCT06832865RecruitingPhase 2
Elranatamab and isatuximab for relapsed multiple myeloma
This trial tests a combination of two drugs—elranatamab and isatuximab—for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see if this new combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Boston, MassachusettsAges 18 years+ - NCT07096778RecruitingPhase 2
Study of Inobrodib, Pomalidomide, and Dexamethasone for Multiple Myeloma
This trial tests a new combination of three drugs—inobrodib, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug adds benefit for patients who have tried other therapies.
Boston, MassachusettsAges 18 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT06083922RecruitingPhase 2
CyBorD plus Daratumumab for kidney disease caused by abnormal proteins
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
Boston, MassachusettsAges 18 years+
Hear when a new Multiple myeloma trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Multiple myeloma trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting multiple myeloma studies listed above.
- Dana-Farber Cancer Institute · 13 studies
- Massachusetts General Hospital · 7 studies
- Beth Israel Deaconess Medical Center · 6 studies
- Research Site · 2 studies
- Tufts Medical Center · 2 studies
- Boston Medical Center
- Brigham and Women's Hospital
- Brown University
What taking part in a multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting multiple myeloma studies in Massachusetts.
Common questions
- Are there multiple myeloma clinical trials near Boston?
- Yes. We're currently tracking 56 recruiting multiple myeloma studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple myeloma study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple myeloma studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.